Clinical Edge Journal Scan

A real-world analysis finds no evidence of increased CV risk with tofacitinib vs. TNFi in RA


 

Key clinical point: Under real-world settings, tofacitinib was not associated with a higher risk for cardiovascular (CV) outcomes compared with tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA); however, the risk could not be ruled out in patients with prior CV disease.

Major finding: Tofacitinib vs. TNFi was not linked with a higher risk for composite CV outcome (pooled weighted hazard ratio [pwHR] 1.01; 95% CI 0.83-1.23); however, the pwHR for patients with and without prior CV disease was 1.27 (95% CI, 0.95-1.70) and 0.81 (95% CI 0.61-1.07), respectively.

Study details: STAR-RA is a multidatabase, population-based study including 1,02,263 patients with RA who initiated treatment with tofacitinib or TNFi.

Disclosures: This study was funded by the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital & Harvard Medical School, Boston, MA, USA. RJ Desai and SC Kim reported receiving research grants from various sources. All the other authors reported no conflicts of interest.

Source: Khosrow-Khavar F et al. Ann Rheum Dis. 2022 (Jan 13). Doi: 10.1136/annrheumdis-2021-221915

Recommended Reading

Upadacitinib inhibits structural joint damage progression in RA
MDedge Rheumatology
Clinical Edge Journal Scan Commentary: RA February 2022
MDedge Rheumatology
Lilly calls it quits on baricitinib’s development for lupus
MDedge Rheumatology
Boxed warning for JAK inhibitors belies their durability in real-world registry studies
MDedge Rheumatology
Dietary recommendations for inflammatory rheumatic diseases
MDedge Rheumatology
Patients are interrupting DMARD use well into the COVID-19 pandemic
MDedge Rheumatology
Treat-to-target in RA: Questions remain about adoption, measurement
MDedge Rheumatology
Rheumatoid arthritis: Higher risk for MACE and cancer with tofacitinib vs. TNF inhibitors
MDedge Rheumatology
More evidence supporting ultra-low retreatment dose of rituximab in RA
MDedge Rheumatology
Acute exacerbation affects prognosis in RA-associated interstitial lung disease
MDedge Rheumatology